Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress
- 70% overall response rate (33/47 patients) at 2 mg dose of SD-101 includes 17 additional patients - -Progression free survival, response rate in patients with PDL-1 negative tumors and biomarker activity supports clinical impact of SD-101’s activity- - Conference call and webcast to review all
View HTML
Toggle Summary Dynavax Technologies and Quantum Leap Healthcare Collaborative Announce Selection of SD-101 Combined with KEYTRUDA® (pembrolizumab) in the I-SPY 2 TRIAL For Breast Cancer
BERKELEY, Calif. and SAN FRANCISCO , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) and Quantum Leap Healthcare Collaborative™ (QLHC) announced today that the immunotherapy combination of Dynavax’s proprietary investigational compound SD-101 and KEYTRUDA®
View HTML
Toggle Summary Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress
BERKELEY, Calif. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data will be presented from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA ® (pembrolizumab), an anti-PD-1
View HTML
Toggle Summary Dynavax to Present at the 2018 Cantor Global Healthcare Conference
BERKELEY, Calif. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that Eddie Gray , Dynavax’s Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on Monday, October 1, 2018 at 10:40 AM ET at the InterContinental
View HTML
Toggle Summary Dynavax Announces Publication of Preclinical Study of TLR9 Agonist in Lung Cancer
Delivery of a TLR9 Agonist Through the Airways Complements PD-1 Blockade to Generate Durable, Systemic Anti-tumor Immunity BERKELEY, Calif. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced publication of a preclinical study demonstrating that
View HTML
Toggle Summary Dynavax Announces Publication of Two Papers in Leading Oncology Journal Highlighting Data From Clinical Studies of Its TLR9 Agonist, SD-101
Cancer Discovery Features Reports of Early Clinical Trials of SD-101 in Lymphoma and Advanced Melanoma BERKELEY, Calif. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that two peer-reviewed papers reporting clinical studies of SD-101 have been
View HTML
Toggle Summary Dynavax Reports Second Quarter 2018 Financial Results
HEPLISAV-B® Launch Progressing as Planned with Key Customer Successes Three abstracts accepted for presentation at European Society for Medical Oncology ( ESMO ) 2018 Annual Meeting Conference Call to be held at 4:30pm ET / 1:30pm PT BERKELEY, Calif. , Aug.
View HTML
Toggle Summary Dynavax to Host Second Quarter 2018 Financial Results Conference Call
Update on HEPLISAV-B® and Timing of Oncology Data BERKELEY, Calif. , July 30, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will report financial results for the second quarter ended June 30, 2018 after market close on Monday, August 6, 2018 , and
View HTML
Toggle Summary Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs
Board Comprises Six Members with Notable Contributions to the Fields of Oncology and Immunology BERKELEY, Calif. , June 28, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced the formation of a six-member Scientific Advisory Board with significant experience in
View HTML
Toggle Summary Dynavax Presents Analysis of Data for Participants Aged 60 to 70 with Diabetes from its Phase 3 Trial of HEPLISAV-B®
In a Post-Hoc Analysis of Elderly Diabetic Patients, HEPLISAV-B was Well-Tolerated and Induced Higher Rates of Seroprotection than Engerix-B Data Presented at 2018 American Diabetes Association Annual Meeting BERKELEY, Calif. , June 25, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation
View HTML